Publication | Closed Access

Safety and efficacy of [Y-90-DOTA,Tyr(3)]-octreotide (Y-90-SMT487; OctreoTher) peptide receptor radionuclide therapy (PRRT). Preliminary results of a phase-1 study

Phase-1 StudyMedicineRadionuclide TherapyPreliminary ResultsRadiopharmaceutical TherapyPharmacotherapyNon-peptide LigandPharmacologyRadiation OncologyNovel Therapy